نتایج جستجو برای: fcεri
تعداد نتایج: 604 فیلتر نتایج به سال:
Omalizumab is an anti-IgE antibody developed for the treatment of atopic diseases.1Cardet J.C. Casale T.B. New insights into utility omalizumab.J Allergy Clin Immunol. 2019; 143: 923-926.e1Abstract Full Text PDF PubMed Scopus (28) Google Scholar It approved moderate to severe persistent allergic asthma and appears be effective other diseases such as rhinitis, food allergy, bronchopulmonary aspe...
Background Atopic dermatitis (AD) is a common skin disease of childhood which may cause debilitating symptoms and greatly impair the quality of life of the patient and his relatives [1]. Treatment of chronic AD usually focuses on topical regimen of emolients and immunosuppressants, although systemic immunosuppressive therapy is sometimes required in more severe cases. Omalizumab is a humanized ...
Immortal mast cell lines, such as RBL-2H3 and HMC-1 cells, are commonly utilized to investigate the function of mast cells. However, they are tumor cells carrying a gain-of-function mutation of Kit. We established an immortal mast cell line without Kit mutation, NCL-2, derived from NC mouse bone marrow. NCL-2 cells could be maintained without additional growth factors and thus could respond to ...
Aspercyclide A (1) is a biaryl ether containing 11-membered macrocyclic natural product antagonist of the human IgE-FcεRI protein-protein interaction (PPI); a key interaction in the signal transduction pathway for allergic disorders such as asthma. Herein we report a novel approach to the synthesis of the C19 methyl ether of aspercyclide A, employing a Pd(0)-catalysed, fluorous-tagged alkenylge...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید